NCT02048787View on ClinicalTrials.gov

Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Renal Impairment
Interventions
DRUG

Buparlisib

Subjects will receive a single dose of 50 mg buparlisib.

Trial Locations (4)

1612

Novartis Investigative Site, Sofia

14050

Novartis Investigative Site, Berlin

140 59

Novartis Investigative Site, Prague

Unknown

Novartis Investigative Site, Bucharest

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY